List of Excipients in Branded Drug TIOCONAZOLE 1

« Back to Dashboard

Generic Drugs Containing TIOCONAZOLE 1

Company	Ingredient	NDC	Excipient
Walgreen Company	tioconazole	0363-0426	BUTYLATED HYDROXYANISOLE
Walgreen Company	tioconazole	0363-0426	MAGNESIUM ALUMINUM SILICATE
Walgreen Company	tioconazole	0363-0426	PETROLATUM
Rite Aid Corporation	tioconazole	11822-0426	BUTYLATED HYDROXYANISOLE

What are the Most Frequently-Used Excipients in TIOCONAZOLE 1?

# Of NDCs	Excipient
8	BUTYLATED HYDROXYANISOLE
8	MAGNESIUM ALUMINUM SILICATE
7	PETROLATUM
1	WHITE PETROLATUM

Tioconazole 1% Excipient Strategy and Commercial Opportunities

Last updated: October 21, 2026

Tioconazole 1% is a mature topical imidazole antifungal opportunity with low active-ingredient cost, limited composition-of-matter protection, and commercial differentiation driven mainly by formulation, delivery, tolerability, packaging, and channel strategy. The most attractive opportunities are nonprescription dermatology products, external vulvovaginal-use products, private-label launches, and preservative-minimized formulations. The principal technical constraint is tioconazole’s very low water solubility, which favors anhydrous, emulsion, suspension, or solvent-assisted systems rather than simple aqueous creams.

What is tioconazole 1% used for?

Tioconazole is an imidazole antifungal active ingredient used against susceptible dermatophytes and yeasts. A 1% product is generally positioned for topical treatment of conditions such as tinea pedis, tinea cruris, tinea corporis, and cutaneous candidiasis, subject to the labeling and regulatory pathway in each market.

Tioconazole vaginal products use a different concentration and product architecture. In the United States, the established single-dose vaginal product is typically tioconazole 6.5% ointment, not tioconazole 1%. A company developing tioconazole 1% must therefore define whether the target is:

• External dermatological cream, ointment, gel, or spray
• External vulvar-use product
• Vaginal cream or gel
• Combination product with a barrier, moisturizer, or antipruritic function
• Private-label or store-brand antifungal product

The concentration cannot be treated as an interchangeable substitute for the approved or monograph-based concentration of another dosage form.

What excipients are suitable for tioconazole 1%?

Tioconazole’s aqueous solubility is poor. Formulation development should begin with solubility and phase-partition screening, followed by viscosity, microbial, preservative, and skin-tolerance studies.

Excipient class	Candidate examples	Primary function	Main development issue
Oleaginous base	White petrolatum, mineral oil, paraffin, microcrystalline wax	Occlusion, emollience, water protection	Greasiness and poor washability
Water-miscible solvent	Propylene glycol, polyethylene glycol 400, glycerol	Solubilization, humectancy	Irritation potential and tack
Emulsifier	Polysorbate 60, polysorbate 80, glyceryl stearate, PEG stearates	Emulsion stability	Sensitivity, peroxide and oxidation concerns
Fatty alcohol	Cetyl alcohol, stearyl alcohol, cetostearyl alcohol	Structure and viscosity	Can alter release and sensory profile
Gelling polymer	Carbomer, hydroxyethylcellulose, hydroxypropylcellulose	Gel structure and suspension	Electrolyte and pH sensitivity
Suspending agent	Colloidal silicon dioxide, bentonite, magnesium aluminum silicate	Controls dispersed active	Texture and dose uniformity
Humectant	Glycerin, propylene glycol, sorbitol	Hydration and skin feel	May increase stinging or microbial burden
Preservative	Phenoxyethanol, benzoic acid, sorbic acid, parabens	Microbial protection	Regulatory and consumer acceptance
Chelator	Disodium EDTA	Preservative support and metal control	Compatibility and labeling
Antioxidant	Tocopherol, BHT, sodium metabisulfite where appropriate	Oxidative stability	Sensitivity and formulation compatibility
pH adjuster	Citric acid, sodium citrate, sodium hydroxide	pH control	Drug stability and skin tolerance

The formulation should not contain an excipient solely because it is common in a comparator. Tioconazole distribution between phases, particle size, polymorphic state, and release from the vehicle can materially affect performance.

Which tioconazole 1% formulation platform offers the best commercial position?

Anhydrous ointment

An anhydrous ointment is technically attractive because it avoids aqueous solubility and reduces microbial-growth risk. Petrolatum-based systems can provide strong barrier properties and long residence time.

The disadvantages are consumer perception, residue, clothing transfer, and poor cosmetic acceptability. An ointment is more suitable for severe dryness, overnight use, or external vulvar application than for broad daytime dermatology use.

Oil-in-water cream

An oil-in-water cream is the broadest commercial platform. It offers better spreadability, washability, and cosmetic acceptability than an ointment. The active can be dissolved partly in a solvent phase or dispersed as a fine solid phase.

A successful cream requires control of:

• Active particle size and agglomeration
• Solvent concentration
• Emulsion droplet size
• Viscosity across storage temperatures
• Drug release from the semisolid base
• Preservative effectiveness
• Phase separation and crystallization

This platform is the strongest candidate for mass-market dermatology and private-label retail products.

Water-miscible gel

A hydroalcoholic or polyol-based gel can deliver a light sensory profile and rapid drying. It may support a differentiated "non-greasy" claim where permitted.

The principal risks are stinging, drying, alcohol-related irritation, active precipitation, and loss of viscosity. A gel is more appropriate for intact skin and limited-area application than for compromised or mucosal tissue unless specifically tested and labeled.

Cream-gel or emulgel

An emulgel combines an emulsion with a polymeric gel network. It can reduce greasiness while maintaining acceptable drug loading. This platform offers a credible formulation patent opportunity if the company develops a reproducible active dispersion, controlled release profile, or stability advantage.

Spray, foam, or wipe

Sprays, foams, and impregnated wipes can create packaging and convenience differentiation. They also increase the regulatory and manufacturing burden. Metered delivery, flammability, propellant selection, preservative exposure, and dose uniformity require specific development work.

What excipient strategy should a company use for tioconazole 1%?

A staged strategy is preferable.

Phase 1: Develop a low-risk reference formulation

The initial formulation should use widely accepted excipients with established topical precedent. A conventional cream or ointment provides the lowest regulatory and technical risk. The objective is to confirm:

• Chemical stability
• Physical stability
• Uniformity of tioconazole content
• Microbial quality
• Preservative effectiveness where applicable
• In vitro release
• Skin compatibility
• Packaging compatibility

Phase 2: Improve sensory performance

The second formulation should target measurable consumer advantages:

• Lower greasiness
• Faster rub-in
• Reduced residue
• Lower tack
• Improved wash-off
• Reduced stinging
• Better compatibility with clothing
• More precise application

These improvements can support brand positioning even where the antifungal active is not differentiated.

Phase 3: Create defensible formulation know-how

A commercial formulation can gain technical defensibility through:

• Stable tioconazole suspension at a defined particle-size range
• Reduced crystallization during accelerated storage
• Controlled release from a semisolid matrix
• Lower solvent concentration with maintained drug release
• Preservative-free multidose packaging
• Airless or unit-dose packaging
• Improved stability under high temperature and humidity
• A specific pH and buffer system that improves tolerability
• A formulation suitable for both skin and external vulvar use

A patent should protect the formulation as a complete system, not only list routine excipient alternatives. Claims directed to narrow, reproducible excipient ratios, particle characteristics, packaging, and performance parameters are more commercially useful than broad lists of conventional ingredients.

What manufacturing and quality barriers affect tioconazole 1%?

The main manufacturing barriers are not raw-material scarcity. They are uniformity, stability, and scale-up control.

Critical process parameters may include:

1. Active milling or controlled particle-size distribution
2. Solvent-phase temperature and mixing order
3. Emulsification energy and homogenization time
4. Cooling rate and crystallization control
5. Deaeration
6. Filling temperature
7. Tube or pump compatibility
8. Batch-to-batch viscosity and drug-release consistency

For a suspension-based cream, inadequate dispersion can produce content nonuniformity and variable release. For a solvent-based system, evaporation during manufacturing or filling can change active concentration and rheology.

Packaging should be selected early. Aluminum tubes, laminated tubes, plastic tubes, airless pumps, sachets, and applicators can differ in extractables, sorption, oxygen transmission, water loss, and dose delivery. Single-use packaging is particularly relevant for vulvovaginal or external intimate-care products because it can reduce preservative requirements and contamination risk.

What FDA regulatory status applies to tioconazole 1%?

The regulatory pathway depends on the indication, route, concentration, claims, and dosage form.

United States topical dermatology

A tioconazole 1% dermatological product may be regulated as an OTC drug if its labeling, active ingredient, concentration, dosage form, and claims fit the applicable FDA OTC antifungal framework. A product outside the monograph conditions may require an approved NDA or another FDA authorization pathway.

The sponsor must not assume that a 1% topical product inherits the regulatory status of tioconazole 6.5% vaginal ointment. Different routes and indications can require separate evidence.

Vaginal and vulvar products

Vaginal products face greater scrutiny for irritation, applicator performance, microbial quality, user instructions, and pregnancy-related labeling. An external vulvar product is not automatically equivalent to an intravaginal product.

FDA Orange Book status

OTC monograph products generally do not have the same Orange Book listing structure as prescription products approved through NDAs. A company should not rely on Orange Book patent information as the primary freedom-to-operate tool for a monograph-based tioconazole 1% product. Relevant analysis should cover FDA regulations, approved product labeling, listed patents where applicable, published applications, formulation patents, trademarks, and state-level requirements.

FDA’s OTC Monograph M005 addresses topical antifungal drug products, while vaginal antifungal products are governed through separate regulatory provisions and product-specific requirements.[1,2]

What patents protect tioconazole 1% products?

Tioconazole’s original composition-of-matter protection is legacy intellectual property. A new tioconazole 1% product is unlikely to obtain meaningful protection from the active ingredient itself.

The relevant patent categories are:

Patent category	Commercial relevance	Expected risk
Composition of matter	Protects tioconazole itself	Generally expired or commercially weak
Basic topical formulation	Covers conventional creams or ointments	Often vulnerable to prior art
Specific excipient system	Can protect unusual ratios or performance	Moderate if technically supported
Particle-size or polymorph claims	Can protect reproducible active form	Depends on prior art and characterization
Method of treatment	May cover selected indications or regimens	Limited by labeling and enforceability
Packaging and applicator	Can protect unit-dose or metered delivery	Useful for differentiated products
Manufacturing process	Covers dispersion, crystallization, or filling	Stronger when process affects product quality
Trade dress and trademarks	Protects commercial identity	Important for OTC products

A formulation patent should include comparative data. Examples include improved stability, lower irritation, faster release, improved retention, or reduced residue against a conventional tioconazole formulation. Without measurable technical effect, routine excipient combinations face substantial obviousness risk.

When does tioconazole lose exclusivity?

Tioconazole is a mature generic and OTC active ingredient. The primary active-ingredient exclusivity period has long ended in major markets. Commercial exclusivity therefore depends on formulation patents, trademarks, distribution contracts, regulatory status, retailer relationships, and manufacturing scale.

For a new 1% product, the relevant launch question is not whether tioconazole itself is exclusive. It is whether the sponsor can establish a differentiated product with:

• A protected dosage form
• A defensible formulation
• A recognized brand
• A private-label contract
• A channel advantage
• A regulatory position that competitors cannot quickly replicate

Are Paragraph IV challenges relevant to tioconazole 1%?

Paragraph IV litigation is most relevant when a generic applicant files an ANDA referencing an approved NDA with listed patents. A conventional OTC monograph-based tioconazole 1% product may not present the same Paragraph IV profile.

Paragraph IV exposure becomes more relevant if a sponsor obtains an NDA for a novel formulation or if a competitor references an approved product with listed patents. Potential disputes could concern formulation composition, manufacturing process, method of use, or an applicator system.

For a mature OTC antifungal, the more probable competitive risks are:

• Fast private-label copying
• Retailer substitution
• Trademark conflict
• Trade dress replication
• Manufacturing undercutting
• Product-quality recalls
• Claims or labeling disputes

What licensing deals and commercial partnerships are available?

Tioconazole 1% has limited value as a standalone licensing asset because the active ingredient is widely available. Licensing value is higher in the following structures:

• A proprietary low-irritation cream base
• A preservative-free package
• A unit-dose intimate-care delivery system
• A co-branded consumer-health product
• A contract-manufactured private-label line
• Regional distribution rights
• A formulation platform that also supports other insoluble antifungals

Potential partners include generic pharmaceutical companies, OTC consumer-health companies, dermatology brands, pharmacy chains, online retailers, and contract development and manufacturing organizations.

The strongest licensing proposition is a finished product with stability data, validated manufacturing, regulatory documentation, packaging, and retailer-ready claims. A formulation concept without supporting data has limited transaction value.

How does tioconazole 1% compare with competing antifungals?

Active ingredient	Common topical positioning	Commercial strength	Key differentiation issue
Tioconazole	Broad topical antifungal and vaginal antifungal heritage	Mature, low-cost	Limited active-ingredient novelty
Clotrimazole	Broad dermatological and vaginal use	High brand and generic familiarity	Heavy competition
Miconazole	Dermatology and vaginal products	Strong consumer recognition	Crowded retail market
Terbinafine	Dermatophyte-focused products	Strong efficacy positioning	Higher active cost and formulation considerations
Tolnaftate	Athlete’s foot and ringworm products	Established OTC niche	Narrower organism positioning
Nystatin	Candida-focused products	Strong prescription and specialty use	Less broad for dermatophytes

Tioconazole 1% is most competitive when the product improves usability or tolerability. It is less likely to win solely through a low price because comparable antifungal products are widely available.

What generic launch risks exist for a tioconazole 1% product?

A conventional cream can face rapid competition once launched. Generic and private-label manufacturers can often reproduce a simple formula using established excipients and standard tube filling.

The main launch risks are:

• Weak differentiation from clotrimazole and miconazole
• Retail price compression
• Inadequate stability in the selected package
• Consumer confusion between external and vaginal use
• Irritation from solvents or preservatives
• Unsubstantiated "fast relief" or "advanced" claims
• Failure to control active uniformity
• Inability to secure adequate manufacturing capacity
• Product returns caused by phase separation or leakage

The most defensible commercial model combines a technically differentiated formulation with a clear use case, such as a low-residue cream for daytime use or a single-use external application format.

What geographic opportunities exist for tioconazole 1%?

The opportunity is global but regulatory classification varies. The same product may be an OTC drug in one market, a pharmacy medicine in another, and a prescription product elsewhere.

Priority markets should be evaluated for:

• OTC monograph or similar pathways
• Local antifungal labeling requirements
• Accepted excipient lists
• Local language and indication restrictions
• Import and manufacturing requirements
• Retail penetration
• Consumer preference for creams, ointments, powders, or sprays
• Availability of local generic competitors

Emerging-market opportunities may favor low-cost creams and ointments. North American and Western European markets provide stronger opportunities for cosmetic acceptability, private-label partnerships, and premium packaging.

What is the revenue opportunity for tioconazole 1%?

Revenue depends more on channel placement than on active-ingredient margin. A simple generic product can have low development cost but also low barriers to entry. A differentiated product can support higher gross margins if it earns premium placement in pharmacy, intimate-care, dermatology, or e-commerce channels.

Commercial model	Margin potential	Development burden	Defensibility
Basic generic cream	Low to moderate	Low	Low
Branded cream	Moderate	Moderate	Moderate through brand
Premium low-residue cream	Moderate to high	Moderate	Moderate
Unit-dose intimate-care product	High	Moderate to high	Moderate to high
Preservative-free pump product	High	High	High if validated
Private-label retailer product	Moderate	Low to moderate	Contract-dependent
Multi-active antifungal platform	High	High	Higher, with regulatory complexity

Key Takeaways

• Tioconazole 1% is a mature, low-cost active with limited composition-of-matter exclusivity.
• The leading formulation platform is an oil-in-water cream using solvent-assisted dissolution or controlled active dispersion.
• Anhydrous ointments reduce microbial risk but are less attractive cosmetically.
• Emulgels, preservative-minimized systems, unit-dose packages, and low-residue creams offer the strongest differentiation.
• FDA status depends on route, indication, concentration, claims, and dosage form. Tioconazole 1% should not be treated as interchangeable with tioconazole 6.5% vaginal ointment.
• Orange Book and Paragraph IV analysis is less central for a conventional OTC monograph product than for an NDA-based product.
• Formulation, manufacturing, packaging, trademarks, and distribution agreements provide the main commercial barriers.
• The best licensing asset is a validated finished product with stability, release, tolerability, packaging, and regulatory data.
• Generic price competition is severe. Commercial success requires a defined use case and measurable product advantage.

FAQs

Can tioconazole 1% be formulated as a water-based cream?

Yes, but the active’s low water solubility requires a solvent-assisted system, fine-particle suspension, emulsion, or emulgel. A simple aqueous solution is generally unsuitable.

Is propylene glycol appropriate for tioconazole 1%?

Propylene glycol can support solubilization and humectancy, but its level should be controlled because it may increase stinging, tack, or irritation, particularly on compromised or mucosal tissue.

Is a preservative-free tioconazole 1% cream commercially feasible?

Yes, particularly in anhydrous or unit-dose packaging. Multidose preservative-free systems require validated microbial control, package integrity, and in-use testing.

Can tioconazole 1% be marketed for vaginal candidiasis?

Not automatically. Vaginal use, external vulvar use, and dermatological use are distinct regulatory and clinical categories. The product concentration, route, claims, applicator, and supporting data must align.

What is the strongest patent strategy for a new tioconazole 1% product?

The strongest strategy usually combines a specific excipient ratio, active particle or dispersion control, measurable stability or release benefits, a defined manufacturing process, and differentiated packaging. Broad claims covering conventional cream ingredients are more vulnerable to prior art.

References

1. U.S. Food and Drug Administration. (2024). OTC monograph M005: Topical antifungal drug products for over-the-counter human use. FDA.

2. U.S. Food and Drug Administration. (2024). Code of Federal Regulations, Title 21, Part 333: Topical antimicrobial drug products for over-the-counter human use. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

4. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.

5. International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products. ICH.

6. International Council for Harmonisation. (2005). Q8(R2): Pharmaceutical development. ICH.